20:30 , Jun 16, 2017 |  BC Week In Review  |  Company News

AbCellera, Teva to discover antibodies targeting undisclosed membrane protein

AbCellera Biologics Inc. (Vancouver, B.C.) will use its antibody screening platform to discover antibodies that modulate the function of an undisclosed membrane protein target selected by Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). AbCellera will...
19:54 , Jan 13, 2017 |  BC Week In Review  |  Company News

AbCellera, Pfizer deal

AbCellera will use its high-throughput single cell antibody platform to discover function-modulating antibodies against multiple undisclosed membrane protein targets. The company will receive an undisclosed upfront payment and research support and is be eligible for...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Company News

Teva, AbCellera deal

AbCellera will use its high-throughput single cell antibody platform to discover mAbs. AbCellera will receive an undisclosed upfront payment and R&D milestones. Teva did not respond to inquiries, and AbCellera declined to disclose additional details....
08:00 , Feb 8, 2016 |  BC Week In Review  |  Company News

AbCellera, Merck deal

AbCellera and Merck will use AbCellera’s microfluidic discovery technology to discover mAbs against an undisclosed target. Merck has the option to develop antibody candidates generated under the deal. The partners declined to provide additional details....